Biowaiver assessment of some commercially available brands of valsartan tablets using in vitro methods
Main Article Content
Abstract
Background: Generic medicines must be therapeutic equivalents with the innovator brand before substitution is appropriate.
Objective: This study was carried out to evaluate the in vitro equivalence of valsartan (a BCS Class III drug) tablets under Biowaiver conditions.
Methods: Physicochemical parameters were assessed in accordance with BP and USP specifications. Therapeutic equivalence of the innovator and commonest generic brands were investigated using in vitro methods.
Results: The tested valsartan brands investigated complied with Compendia specifications for tablets. Valsartan tablets were not very rapidly dissolving as per WHO Biowaiver testing specifications. Both test and reference products were poorly soluble in acidic medium (pH 1.2), while 85% of the drug was released at 15 minutes in pH 6.8. Dissolution profiles of the test and innovator brands were similar at pH 1.2 and 6.8 (f2: 65 and 69 respectively), and dissimilar at pH 4.5 (f2: 30). The generic valsartan tablets evaluated in this study showed pharmaceutical equivalence with the innovator brand. The test and reference products were not however very rapidly dissolving as required for BCS Class III drugs.
Conclusion: The valsartan tablet brands tested did not meet WHO BCS-based biowaiver conditions. In vivo bioequivalence studies are recommended to ascertain therapeutic equivalence and interchangeability.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
How to Cite
Share
References
Waiver of In vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Or al Dosage Forms Based on a Biopharmaceutics Classification System; Guidance for Industry; U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), U.S. Government Printing Office: Washington, DC, August 2000. Available at:http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid ances/ucm070246.pdf. Accessed March 11,2015.
Yu LX, Amidon GL, Polli JE, Zhao H, Mehta MU, Conner DP, Shah VP, Lesko LJ, Chen M, Lee VHL, Hussain AS (2002). Biopharmaceutics
Classification System: The Scientific Basis for Biowaiver Extensions. Pharmaceutical Research, 19: 921-925.
WHO Expert Committee on Specifications for Pharmaceutical Preparations. Proposal to waive in vivo bioequivalence requirements for
WHO Model List of Essential Medicines immediate-release, solid oral dosage forms; WHO Technical Report Series, No. 937, Annex 7; World Health Organization: Geneva, Switzerland, 2006. http://whqlibdoc.who.int/trs/WHO_TRS_937_eng.pdf. Accessed March 6, 2015.
Gupta E, Barends D, Yamashita E (2006). Review of global regulations concerning biowaivers for immediate release solid oral dosage forms.
European Journal of Pharmaceutical Sciences 9: 315-324.
Polli J (2008). In vitro Studies are Sometimes Better than Conventional Human Pharmacokinetic In vivo Studies in Assessing Bioequivalence of Immediate-Release Solid Oral Dosage Forms. The AAPS Journal 10: 289-299.
Flesch G, Lloyd P, Müller P (1997). Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. European Journal of Clinical Pharmacology 52: 115-120.
Nissankararao S, Kumar A, Sravanthi S (2013). Method development and validation for the estimation of valsartan in bulk and tablet
dosage forms by RP-HPLC. Der Pharma Chem5:2 06–211.
Amidon G, Lennernas H, Shah V (1995). A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug
product and in vivo bioavailability. Pharmaceutical Research 12: 413-420.
Wu C, Benet L (2005). Predicting drug disposition via application of BCS: transport/ absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharmaceutical Research 22: 11-23.
United States Pharmacopoeia, USP 35 NF 30, the United States Pharmacopoeial Convention, Inc., 2012.
Cook J, Bockbrader H (2002). An Industrial Implementation of the Biopharmaceutics Classification System. Dissolution Technology9: 6–8.
Lobenberg R, Amidon G (2000). Modern bio availability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. European Journal of Pharmaceutics and Biopharmaceutics 50:3–12.
Gothoskar A (2005). Biopharmaceutical classification of drugs [online]. Pharmaceutics Review, 3 (2005). http://www.pharmainfo.net/reviews/biopharmaceutical-classification-drugs. Accessed March 11,2015.
Saydam M, Takka S (2007). Bioavailability File: Valsartan'. FABAD Journal of Pharmaceutical Sciences 32: 185-196.
Jantratid E, Prakongpan S, Amidon G (2006). Feasibility of biowaiver extension of biopharmaceutics classification system class III drug products cimetidine. Clinical Pharmacokinetics 45: 385-399.
Crison J, Timmins P, Keung A (2012). Journal of Pharmaceutical Sciences 101: 1773-1782.
Cheng C, Yu L, Lee H (2004). Biowaiver extension potential to BCS Class III high solubility-low permeability drugs: bridging evidence for metformin immediate-release tablet. European Journal of Pharmaceutical Sciences 22: 297-304.
Homsek I, Parojcić J, Dacević D (2010). Justification of Metformin hydrochloride biowaiver criteria based on Bioequivalence study. Arzneimittelforschung, Available at http://www.thieme-connect.com/Doi/Doi?10.1055/s-0031-1296324. Accessed February 14, 2015.
Polli J, Yu L, Cook J (2003). Summary workshop report: Biopharmaceutics classification system-implementation challenges and extension opportunities. Journal of Pharmaceutical Sciences 93: 1375–1381.
Blume H , Schug B (1999). The biopharmaceutics classification system (BCS): class III drugs—better candidates for BA/BE waiver? European Journal of Pharmaceutical Sciences 9:117–121.
Kortejarvi H, Yliperttula M, Dressman J (2005). Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Ranitidine
Hydrochloride. Journal of Pharmaceutical Sciences 94: 1617–1625.